ID   NTRK1_HUMAN             Reviewed;         796 AA.
AC   P04629; B2R6T5; B7ZM34; P08119; Q15655; Q15656; Q5D056; Q5VZS2;
AC   Q7Z5C3; Q9UIU7;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 4.
DT   02-NOV-2010, entry version 155.
DE   RecName: Full=High affinity nerve growth factor receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 1;
DE   AltName: Full=TRK1-transforming tyrosine kinase protein;
DE   AltName: Full=p140-TrkA;
DE            Short=Trk-A;
DE   Flags: Precursor;
GN   Name=NTRK1; Synonyms=TRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKA-I).
RC   TISSUE=Colon;
RX   MEDLINE=89181575; PubMed=2927393;
RA   Martin-Zanca D., Oskam R., Mitra G., Copeland T.D., Barbacid M.;
RT   "Molecular and biochemical characterization of the human trk proto-
RT   oncogene.";
RL   Mol. Cell. Biol. 9:24-33(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=95123473; PubMed=7823156;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=97435581; PubMed=9290260; DOI=10.1007/BF02766957;
RA   Indo Y., Mardy S., Tsuruta M., Karim M.A., Matsuda I.;
RT   "Structure and organization of the human TRKA gene encoding a high
RT   affinity receptor for nerve growth factor.";
RL   Jpn. J. Hum. Genet. 42:343-351(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKA-II).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS TRKA-I AND TRKA-II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-71.
RX   PubMed=15870692; DOI=10.1038/sj.onc.1208697;
RA   Fujimoto M., Kitazawa R., Maeda S., Kitazawa S.;
RT   "Methylation adjacent to negatively regulating AP-1 site reactivates
RT   TrkA gene expression during cancer progression.";
RL   Oncogene 24:5108-5118(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TPM3.
RX   MEDLINE=86146854; PubMed=2869410; DOI=10.1038/319743a0;
RA   Martin-Zanca D., Hughes S.H., Barbacid M.;
RT   "A human oncogene formed by the fusion of truncated tropomyosin and
RT   protein tyrosine kinase sequences.";
RL   Nature 319:743-748(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796.
RX   MEDLINE=88196074; PubMed=2966065;
RA   Kozma S.C., Redmond S.M.S., Saurer S.M., Groner B., Hynes N.E.;
RT   "Activation of the receptor kinase domain of the trk oncogene by
RT   recombination with two different cellular sequences.";
RL   EMBO J. 7:147-154(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TFG.
RX   MEDLINE=96025992; PubMed=7565764;
RA   Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M.,
RA   Pierotti M.A.;
RT   "The DNA rearrangement that generates the TRK-T3 oncogene involves a
RT   novel gene on chromosome 3 whose product has a potential coiled-coil
RT   domain.";
RL   Mol. Cell. Biol. 15:6118-6127(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 486-796, AND CHROMOSOMAL REARRANGEMENT
RP   WITH TPR.
RX   PubMed=1532241;
RA   Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C.,
RA   Della Porta G.;
RT   "TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes
RT   in human papillary thyroid carcinomas.";
RL   Oncogene 7:237-242(1992).
RN   [12]
RP   FUNCTION.
RX   MEDLINE=91218846; PubMed=1850821; DOI=10.1038/350678a0;
RA   Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V.;
RT   "High-affinity NGF binding requires coexpression of the trk proto-
RT   oncogene and the low-affinity NGF receptor.";
RL   Nature 350:678-683(1991).
RN   [13]
RP   FUNCTION.
RX   MEDLINE=91191557; PubMed=1849459; DOI=10.1016/0092-8674(91)90419-Y;
RA   Klein R., Jing S., Nanduri V., O'Rourke E., Barbacid M.;
RT   "The trk proto-oncogene encodes a receptor for nerve growth factor.";
RL   Cell 65:189-197(1991).
RN   [14]
RP   ALTERNATIVE SPLICING.
RX   MEDLINE=93315496; PubMed=8325889;
RA   Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J.,
RA   Shooter E.M.;
RT   "Tissue-specific alternative splicing generates two isoforms of the
RT   trkA receptor.";
RL   J. Biol. Chem. 268:15150-15157(1993).
RN   [15]
RP   MUTAGENESIS OF TYR-791.
RX   MEDLINE=94179299; PubMed=7510697;
RA   Loeb D.M., Stephens R.M., Copeland T.D., Kaplan D.R., Greene L.A.;
RT   "A Trk nerve growth factor (NGF) receptor point mutation affecting
RT   interaction with phospholipase C-gamma 1 abolishes NGF-promoted
RT   peripherin induction but not neurite outgrowth.";
RL   J. Biol. Chem. 269:8901-8910(1994).
RN   [16]
RP   MUTAGENESIS OF TYR-496 AND TYR-791, AND PHOSPHORYLATION AT TYR-496 AND
RP   TYR-791.
RX   MEDLINE=94206546; PubMed=8155326; DOI=10.1016/0896-6273(94)90223-2;
RA   Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A.,
RA   Kaplan D.R.;
RT   "Trk receptors use redundant signal transduction pathways involving
RT   SHC and PLC-gamma 1 to mediate NGF responses.";
RL   Neuron 12:691-705(1994).
RN   [17]
RP   INTERACTION WITH SQSTM1.
RX   PubMed=11244088; DOI=10.1074/jbc.C000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T.,
RA   Barker P.A., Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold
RT   for NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [18]
RP   STRUCTURE BY NMR OF 489-500.
RX   MEDLINE=96097066; PubMed=8524391; DOI=10.1038/378584a0;
RA   Zhou M.-M., Ravichandran K.S., Olejniczak E.F., Petros A.M.,
RA   Meadows R.P., Sattler M., Harlan J.E., Wade W.S., Burakoff S.J.,
RA   Fesik S.W.;
RT   "Structure and ligand recognition of the phosphotyrosine binding
RT   domain of Shc.";
RL   Nature 378:584-592(1995).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 278-386.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M.,
RA   Reilly D., Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB
RT   and TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 282-382.
RX   PubMed=10490030; DOI=10.1038/43705;
RA   Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M.;
RT   "Crystal structure of nerve growth factor in complex with the ligand-
RT   binding domain of the TrkA receptor.";
RL   Nature 401:184-188(1999).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 36-382 IN COMPLEX WITH NGF,
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-95; ASN-121; ASN-188;
RP   ASN-262; ASN-281 AND ASN-358.
RX   PubMed=17196528; DOI=10.1016/j.neuron.2006.09.034;
RA   Wehrman T., He X., Raab B., Dukipatti A., Blau H., Garcia K.C.;
RT   "Structural and mechanistic insights into nerve growth factor
RT   interactions with the TrkA and p75 receptors.";
RL   Neuron 53:25-38(2007).
RN   [22]
RP   VARIANT CIPA ARG-577.
RX   MEDLINE=96331294; PubMed=8696348; DOI=10.1038/ng0896-485;
RA   Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Ohta K., Kawano T.,
RA   Mitsubuchi H., Tonoki H., Awaya Y., Matsuda I.;
RT   "Mutations in the TRKA/NGF receptor gene in patients with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Nat. Genet. 13:485-488(1996).
RN   [23]
RP   VARIANT CIPA PRO-780.
RX   MEDLINE=99192367; PubMed=10090906; DOI=10.1086/302319;
RA   Greco A., Villa R., Tubino B., Romano L., Penso D., Pierotti M.A.;
RT   "A novel NTRK1 mutation associated with congenital insensitivity to
RT   pain with anhidrosis.";
RL   Am. J. Hum. Genet. 64:1207-1210(1999).
RN   [24]
RP   VARIANTS CIPA PRO-213; TRP-649 AND SER-714, AND VARIANTS SER-85;
RP   TYR-604 AND VAL-613.
RX   MEDLINE=99264238; PubMed=10330344; DOI=10.1086/302422;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Sztriha L., Frossard P.,
RA   Moosa A., Ismail E.A.R., Macaya A., Andria G., Toscano E., Gibson W.,
RA   Graham G.E., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis: novel mutations in
RT   the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve
RT   growth factor.";
RL   Am. J. Hum. Genet. 64:1570-1579(1999).
RN   [25]
RP   VARIANTS TYR-604; VAL-613 AND GLN-780.
RX   MEDLINE=99371280; PubMed=10443680; DOI=10.1210/jc.84.8.2784;
RA   Gimm O., Greco A., Hoang-Vu C., Dralle H., Pierotti M.A., Eng C.;
RT   "Mutation analysis reveals novel sequence variants in NTRK1 in
RT   sporadic human medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:2784-2787(1999).
RN   [26]
RP   VARIANT CIPA VAL-587.
RX   MEDLINE=99250414; PubMed=10233776;
RX   DOI=10.1046/j.1523-1747.1999.00569.x;
RA   Yotsumoto S., Setoyama M., Hozumi H., Mizoguchi S., Fukumaru S.,
RA   Kobayashi K., Saheki T., Kanzaki T.;
RT   "A novel point mutation affecting the tyrosine kinase domain of the
RT   TRKA gene in a family with congenital insensitivity to pain with
RT   anhidrosis.";
RL   J. Invest. Dermatol. 112:810-814(1999).
RN   [27]
RP   VARIANTS TYR-604 AND VAL-613.
RX   MEDLINE=99318093; PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [28]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [29]
RP   VARIANT CIPA LEU-695, AND VARIANT VAL-613.
RC   TISSUE=Peripheral blood;
RX   MEDLINE=20321341; PubMed=10861667;
RX   DOI=10.1002/1096-8628(20000619)92:5<353::AID-AJMG12>3.0.CO;2-C;
RA   Shatzky S., Moses S., Levy J., Pinsk V., Hershkovitz E., Herzog L.,
RA   Shorer Z., Luder A., Parvari R.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA) in Israeli-
RT   Bedouins: genetic heterogeneity, novel mutations in the TRKA/NGF
RT   receptor gene, clinical findings, and results of nerve conduction
RT   studies.";
RL   Am. J. Med. Genet. 92:353-360(2000).
RN   [30]
RP   VARIANTS CIPA PRO-93; ARG-522; ARG-577; CYS-654 AND TYR-674.
RX   MEDLINE=20435070; PubMed=10982191; DOI=10.1007/s004390051018;
RA   Miura Y., Mardy S., Awaya Y., Nihei K., Endo F., Matsuda I., Indo Y.;
RT   "Mutation and polymorphism analysis of the TRKA (NTRK1) gene encoding
RT   a high-affinity receptor for nerve growth factor in congenital
RT   insensitivity to pain with anhidrosis (CIPA) families.";
RL   Hum. Genet. 106:116-124(2000).
RN   [31]
RP   VARIANT CIPA ARG-577.
RX   MEDLINE=20036616; PubMed=10567924;
RX   DOI=10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0;
RA   Greco A., Villa R., Fusetti L., Orlandi R., Pierotti M.A.;
RT   "The Gly571Arg mutation, associated with the autonomic and sensory
RT   disorder congenital insensitivity to pain with anhidrosis, causes the
RT   inactivation of the NTRK1/nerve growth factor receptor.";
RL   J. Cell. Physiol. 182:127-133(2000).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-80; VAL-107; MET-237; GLY-238;
RP   GLY-260; GLN-444; CYS-452; THR-566; TYR-604; VAL-613; GLN-780 AND
RP   ILE-790.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Required for high-affinity binding to nerve growth
CC       factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-
CC       derived neurotrophic factor (BDNF). Known substrates for the Trk
CC       receptors are SHC1, PI 3-kinase, and PLC-gamma-1. Has a crucial
CC       role in the development and function of the nociceptive reception
CC       system as well as establishment of thermal regulation via
CC       sweating. Activates ERK1 by either SHC1- or PLC-gamma-1-dependent
CC       signaling pathway.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Binds SH2B2.
CC       Interacts with SQSTM1 which bridges NTRK1 to NGFR. Interacts with
CC       KIDINS220 and NGFR. Can form a ternary complex with NGFR and
CC       KIDINS220 and this complex is affected by the expression levels of
CC       KIDINS220. An increase in KIDINS220 expression leads to a
CC       decreased association of NGFR and NTRK1 (By similarity).
CC   -!- INTERACTION:
CC       Q05209:PTPN12; NbExp=1; IntAct=EBI-1028226, EBI-2266035;
CC       Q9Y2R2:PTPN22; NbExp=1; IntAct=EBI-1028226, EBI-1211241;
CC       P23467:PTPRB; NbExp=1; IntAct=EBI-1028226, EBI-1265766;
CC       P08575:PTPRC; NbExp=1; IntAct=EBI-1028226, EBI-1341;
CC       P23470:PTPRG; NbExp=1; IntAct=EBI-1028226, EBI-2258115;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-1028226, EBI-2264500;
CC       Q16827:PTPRO; NbExp=1; IntAct=EBI-1028226, EBI-723739;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein (By similarity). Note=Endocytosed to the endosomes upon
CC       treatment of cells with NGF (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Both isoforms have similar biological properties;
CC       Name=TrkA-II;
CC         IsoId=P04629-1; Sequence=Displayed;
CC       Name=TrkA-I;
CC         IsoId=P04629-2; Sequence=VSP_002899;
CC   -!- TISSUE SPECIFICITY: Isoform TrkA-II is primarily expressed in
CC       neuronal cells; isoform TrkA-I is found in non-neuronal tissues.
CC   -!- DOMAIN: The transmembrane domain mediates interaction with
CC       KIDINS220 (By similarity).
CC   -!- DOMAIN: The extracellular domain mediates interaction with NGFR
CC       (By similarity).
CC   -!- PTM: Ligand-mediated auto-phosphorylation. Interaction with SQSTM1
CC       is phosphotyrosine-dependent.
CC   -!- DISEASE: Defects in NTRK1 are a cause of congenital insensitivity
CC       to pain with anhidrosis (CIPA) [MIM:256800]. CIPA is characterized
CC       by a congenital insensitivity to pain, anhidrosis (absence of
CC       sweating), absence of reaction to noxious stimuli, self-mutilating
CC       behavior, and mental retardation. This rare autosomal recessive
CC       disorder is also known as congenital sensory neuropathy with
CC       anhidrosis or hereditary sensory and autonomic neuropathy type IV
CC       or familial dysautonomia type II.
CC   -!- DISEASE: Defects in NTRK1 are a cause of thyroid papillary
CC       carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid
CC       that typically arises as an irregular, solid or cystic mass from
CC       otherwise normal thyroid tissue. Papillary carcinomas are
CC       malignant neoplasm characterized by the formation of numerous,
CC       irregular, finger-like projections of fibrous stroma that is
CC       covered with a surface layer of neoplastic epithelial cells.
CC       Note=Chromosomal aberrations involving NTRK1 are found in thyroid
CC       papillary carcinomas. Translocation t(1;3)(q21;q11) with TFG
CC       generates the TRKT3 (TRK-T3) transcript by fusing TFG to the 3'-
CC       end of NTRK1; a rearrangement with TPM3 generates the TRK
CC       transcript by fusing TPM3 to the 3'-end of NTRK1.
CC   -!- DISEASE: Chromosomal aberrations involving NTRK1 are a cause of
CC       thyroid papillary carcinoma (PACT) [MIM:188550]. Intrachromosomal
CC       rearrangement that links the protein kinase domain of NTRK1 to the
CC       5'-end of the TPR gene forms the fusion protein TRK-T1. TRK-T1 is
CC       a 55 kDa protein reacting with antibodies against the C-terminus
CC       of the NTRK1 protein.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 3 LRR (leucine-rich) repeats.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH62580.1; Type=Erroneous initiation;
CC       Sequence=CAA27243.1; Type=Erroneous initiation;
CC       Sequence=CAA29888.1; Type=Erroneous initiation;
CC       Sequence=CAA44719.1; Type=Erroneous initiation;
CC       Sequence=CAA59936.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/NTRK1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23102; AAA36770.1; -; mRNA.
DR   EMBL; AB019488; BAA34355.1; -; Genomic_DNA.
DR   EMBL; AL158169; CAH70010.1; -; Genomic_DNA.
DR   EMBL; AK312704; BAG35582.1; -; mRNA.
DR   EMBL; BC062580; AAH62580.1; ALT_INIT; mRNA.
DR   EMBL; BC136554; AAI36555.1; -; mRNA.
DR   EMBL; BC144239; AAI44240.1; -; mRNA.
DR   EMBL; AY321513; AAP88292.1; -; Genomic_DNA.
DR   EMBL; X03541; CAA27243.1; ALT_INIT; mRNA.
DR   EMBL; X06704; CAA29888.1; ALT_INIT; mRNA.
DR   EMBL; X85960; CAA59936.1; ALT_INIT; mRNA.
DR   EMBL; X62947; CAA44719.1; ALT_INIT; mRNA.
DR   IPI; IPI00025076; -.
DR   IPI; IPI00514519; -.
DR   PIR; A30124; TVHUTT.
DR   PIR; S23741; S23741.
DR   RefSeq; NP_001007793.1; -.
DR   RefSeq; NP_001012331.1; -.
DR   RefSeq; NP_002520.2; -.
DR   UniGene; Hs.406293; -.
DR   PDB; 1HE7; X-ray; 2.00 A; A=285-413.
DR   PDB; 1SHC; NMR; -; B=489-500.
DR   PDB; 1WWA; X-ray; 2.50 A; X/Y=278-386.
DR   PDB; 1WWW; X-ray; 2.20 A; X/Y=282-382.
DR   PDB; 2IFG; X-ray; 3.40 A; A/B=36-382.
DR   PDBsum; 1HE7; -.
DR   PDBsum; 1SHC; -.
DR   PDBsum; 1WWA; -.
DR   PDBsum; 1WWW; -.
DR   PDBsum; 2IFG; -.
DR   ProteinModelPortal; P04629; -.
DR   SMR; P04629; 477-787.
DR   DIP; DIP-1060N; -.
DR   DIP; DIP-5714N; -.
DR   IntAct; P04629; 13.
DR   MINT; MINT-124106; -.
DR   STRING; P04629; -.
DR   PhosphoSite; P04629; -.
DR   PRIDE; P04629; -.
DR   Ensembl; ENST00000358660; ENSP00000351486; ENSG00000198400.
DR   GeneID; 4914; -.
DR   KEGG; hsa:4914; -.
DR   UCSC; uc001fqh.1; human.
DR   UCSC; uc001fqi.1; human.
DR   CTD; 4914; -.
DR   GeneCards; GC01P156786; -.
DR   HGNC; HGNC:8031; NTRK1.
DR   HPA; CAB004606; -.
DR   MIM; 164970; gene.
DR   MIM; 188550; phenotype.
DR   MIM; 191315; gene.
DR   MIM; 256800; phenotype.
DR   Orphanet; 642; Hereditary sensory and autonomic neuropathy type 4.
DR   Orphanet; 64752; Hereditary sensory and autonomic neuropathy type 5.
DR   PharmGKB; PA31817; -.
DR   eggNOG; prNOG17696; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; P04629; -.
DR   OMA; SCGVPTL; -.
DR   PhylomeDB; P04629; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; trkrpathway; Neurotrophic factor-mediated Trk receptor signaling.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; pi3kplctrkpathway; Trk receptor signaling mediated by PI3K and PLC-gamma.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   DrugBank; DB00619; Imatinib.
DR   NextBio; 18907; -.
DR   ArrayExpress; P04629; -.
DR   Bgee; P04629; -.
DR   Genevestigator; P04629; -.
DR   GermOnline; ENSG00000198400; Homo sapiens.
DR   GO; GO:0005768; C:endosome; EXP:Reactome.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kin...; TAS:ProtInc.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; EXP:Reactome.
DR   GO; GO:0007265; P:Ras protein signal transduction; EXP:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kin...; EXP:Reactome.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR020777; Tyr_prot_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_prot_kinase_rcpt_2_CS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 2.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF284; Tyr_prot_kinase_NGF_rcpt; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Complete proteome; Developmental protein;
KW   Differentiation; Disease mutation; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane;
KW   Neurogenesis; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     32       Potential.
FT   CHAIN        33    796       High affinity nerve growth factor
FT                                receptor.
FT                                /FTId=PRO_0000016724.
FT   TOPO_DOM     33    423       Extracellular (Potential).
FT   TRANSMEM    424    439       Helical; (Potential).
FT   TOPO_DOM    440    796       Cytoplasmic (Potential).
FT   REPEAT       90    113       LRR 1.
FT   REPEAT      115    137       LRR 2.
FT   REPEAT      139    161       LRR 3.
FT   DOMAIN      194    283       Ig-like C2-type 1.
FT   DOMAIN      299    365       Ig-like C2-type 2.
FT   DOMAIN      510    781       Protein kinase.
FT   NP_BIND     516    524       ATP (By similarity).
FT   REGION      469    490       Interaction with SQSTM1 (By similarity).
FT   ACT_SITE    650    650       Proton acceptor (By similarity).
FT   BINDING     544    544       ATP (By similarity).
FT   SITE        398    399       Breakpoint for translocation to form TRK
FT                                and TRK-T3.
FT   SITE        486    486       Breakpoint for translocation to form TRK-
FT                                T1.
FT   SITE        496    496       Interaction with SHC1.
FT   SITE        791    791       Interaction with PLC-gamma-1.
FT   MOD_RES     496    496       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     676    676       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     680    680       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     681    681       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     791    791       Phosphotyrosine; by autocatalysis.
FT   CARBOHYD     67     67       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     95     95       N-linked (GlcNAc...).
FT   CARBOHYD    121    121       N-linked (GlcNAc...).
FT   CARBOHYD    188    188       N-linked (GlcNAc...).
FT   CARBOHYD    202    202       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    253    253       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    262    262       N-linked (GlcNAc...).
FT   CARBOHYD    281    281       N-linked (GlcNAc...).
FT   CARBOHYD    318    318       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    323    323       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    338    338       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    358    358       N-linked (GlcNAc...).
FT   CARBOHYD    401    401       N-linked (GlcNAc...) (Potential).
FT   DISULFID    154    191
FT   DISULFID    215    265
FT   VAR_SEQ     393    398       Missing (in isoform TrkA-I).
FT                                /FTId=VSP_002899.
FT   VARIANT      18     18       G -> E (in dbSNP:rs1007211).
FT                                /FTId=VAR_049714.
FT   VARIANT      80     80       Q -> R (in dbSNP:rs55891455).
FT                                /FTId=VAR_041461.
FT   VARIANT      85     85       R -> S.
FT                                /FTId=VAR_009623.
FT   VARIANT      93     93       L -> P (in CIPA).
FT                                /FTId=VAR_009624.
FT   VARIANT     107    107       A -> V (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041462.
FT   VARIANT     213    213       L -> P (in CIPA).
FT                                /FTId=VAR_009625.
FT   VARIANT     237    237       T -> M (in dbSNP:rs55909005).
FT                                /FTId=VAR_041463.
FT   VARIANT     238    238       V -> G (in dbSNP:rs56000394).
FT                                /FTId=VAR_041464.
FT   VARIANT     260    260       R -> G (in dbSNP:rs35116695).
FT                                /FTId=VAR_041465.
FT   VARIANT     444    444       R -> Q (in dbSNP:rs56320207).
FT                                /FTId=VAR_041466.
FT   VARIANT     452    452       R -> C (in dbSNP:rs34900547).
FT                                /FTId=VAR_041467.
FT   VARIANT     522    522       G -> R (in CIPA).
FT                                /FTId=VAR_009626.
FT   VARIANT     566    566       M -> T (in dbSNP:rs55892037).
FT                                /FTId=VAR_041468.
FT   VARIANT     577    577       G -> R (in CIPA; loss of function).
FT                                /FTId=VAR_004103.
FT   VARIANT     587    587       M -> V (in CIPA).
FT                                /FTId=VAR_009627.
FT   VARIANT     604    604       H -> Y (in dbSNP:rs6336).
FT                                /FTId=VAR_009628.
FT   VARIANT     613    613       G -> V (in dbSNP:rs6339).
FT                                /FTId=VAR_009629.
FT   VARIANT     649    649       R -> W (in CIPA).
FT                                /FTId=VAR_009630.
FT   VARIANT     654    654       R -> C (in CIPA).
FT                                /FTId=VAR_009631.
FT   VARIANT     674    674       D -> Y (in CIPA).
FT                                /FTId=VAR_009632.
FT   VARIANT     695    695       P -> L (in CIPA).
FT                                /FTId=VAR_009633.
FT   VARIANT     714    714       G -> S (in CIPA).
FT                                /FTId=VAR_009634.
FT   VARIANT     780    780       R -> P (in CIPA; loss of function).
FT                                /FTId=VAR_009635.
FT   VARIANT     780    780       R -> Q (in dbSNP:rs35669708).
FT                                /FTId=VAR_009636.
FT   VARIANT     790    790       V -> I (in dbSNP:rs55948542).
FT                                /FTId=VAR_041469.
FT   MUTAGEN     496    496       Y->F: No phosphorylation of SHC1.
FT   MUTAGEN     544    544       K->N: Inactive.
FT   MUTAGEN     791    791       Y->F: No phosphorylation of PLC-gamma-1.
FT                                Lack of NGF-promoted increase of the
FT                                peripherin protein.
FT   CONFLICT    263    263       V -> L (in Ref. 1 and 2).
FT   CONFLICT    300    300       C -> S (in Ref. 1; AAA36770).
FT   CONFLICT    529    529       C -> S (in Ref. 10; CAA59936).
FT   CONFLICT    765    766       QR -> HG (in Ref. 9; CAA29888).
FT   CONFLICT    769    796       QQRHSIKDVHARLQALAQAPPVYLDVLG -> SNATASRMC
FT                                TPGCKPWPRHLLSTWMSWARGPAQGLGVVSRNTGACPQHPP
FT                                (in Ref. 9; CAA27243).
FT   STRAND       38     40
FT   STRAND       43     46
FT   TURN         57     61
FT   STRAND       69     72
FT   HELIX        84     86
FT   STRAND       94     97
FT   HELIX       110    112
FT   STRAND      119    121
FT   TURN        133    135
FT   STRAND      142    144
FT   HELIX       154    156
FT   HELIX       157    164
FT   HELIX       171    173
FT   STRAND      178    181
FT   STRAND      195    199
FT   STRAND      211    218
FT   STRAND      227    230
FT   STRAND      234    238
FT   STRAND      244    253
FT   TURN        257    260
FT   STRAND      263    265
FT   STRAND      285    290
FT   STRAND      298    309
FT   STRAND      312    317
FT   STRAND      326    333
FT   STRAND      342    350
FT   HELIX       353    355
FT   STRAND      357    365
FT   STRAND      368    376
FT   TURN        494    496
SQ   SEQUENCE   796 AA;  87497 MW;  6C15C721E336B601 CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPVSFSPVDT NSTSGDPVEK KDETPFGVSV
     AVGLAVFACL FLSTLLLVLN KCGRRNKFGI NRPAVLAPED GLAMSLHFMT LGGSSLSPTE
     GKGSGLQGHI IENPQYFSDA CVHHIKRRDI VLKWELGEGA FGKVFLAECH NLLPEQDKML
     VAVKALKEAS ESARQDFQRE AELLTMLQHQ HIVRFFGVCT EGRPLLMVFE YMRHGDLNRF
     LRSHGPDAKL LAGGEDVAPG PLGLGQLLAV ASQVAAGMVY LAGLHFVHRD LATRNCLVGQ
     GLVVKIGDFG MSRDIYSTDY YRVGGRTMLP IRWMPPESIL YRKFTTESDV WSFGVVLWEI
     FTYGKQPWYQ LSNTEAIDCI TQGRELERPR ACPPEVYAIM RGCWQREPQQ RHSIKDVHAR
     LQALAQAPPV YLDVLG
//
